Guido Kobbe

12.3k total citations
204 papers, 5.2k citations indexed

About

Guido Kobbe is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Guido Kobbe has authored 204 papers receiving a total of 5.2k indexed citations (citations by other indexed papers that have themselves been cited), including 164 papers in Hematology, 55 papers in Genetics and 53 papers in Oncology. Recurrent topics in Guido Kobbe's work include Acute Myeloid Leukemia Research (107 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Multiple Myeloma Research and Treatments (39 papers). Guido Kobbe is often cited by papers focused on Acute Myeloid Leukemia Research (107 papers), Hematopoietic Stem Cell Transplantation (85 papers) and Multiple Myeloma Research and Treatments (39 papers). Guido Kobbe collaborates with scholars based in Germany, United States and Netherlands. Guido Kobbe's co-authors include Rainer Haas, Roland Fenk, Thomas Schroeder, Ingmar Bruns, Ulrich Germing, Ulrich Germing, Nicolaus Kröger, Christina Rautenberg, Akos Czibere and Ralf Kronenwett and has published in prestigious journals such as Nature Genetics, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Guido Kobbe

187 papers receiving 5.1k citations

Peers

Guido Kobbe
Comparison fields: 5 of 110
  • Hematology 3.8k
  • Genetics 1.3k
  • Oncology 1.3k
  • Molecular Biology 1.1k
  • Public Health, Environmental and Occupational Health 1.0k
Uday Popat United States
Ghulam Mufti United Kingdom
Nicolas Boissel France
Yang O. Huh United States
Sherry Pierce United States
Jean‐Michel Cayuela France
Diane C. Arthur United States
Petra Muus Netherlands
Sally Arai United States
Attilio Olivieri Italy
Uday Popat United States View profile →
Citations per field, relative to Guido Kobbe
Guido Kobbe · 1×
Citations per year, relative to Guido Kobbe
Guido Kobbe · 1×

Countries citing papers authored by Guido Kobbe

Since Specialization
Citations

This map shows the geographic impact of Guido Kobbe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Kobbe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Kobbe more than expected).

Fields of papers citing papers by Guido Kobbe

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Guido Kobbe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Kobbe. The network helps show where Guido Kobbe may publish in the future.

Co-authorship network of co-authors of Guido Kobbe

This figure shows the co-authorship network connecting the top 25 collaborators of Guido Kobbe. A scholar is included among the top collaborators of Guido Kobbe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Guido Kobbe. Guido Kobbe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 Characteristics of infections after BCMA-directed CAR T-cell therapy for multiple myeloma: a real-world analysis Blood Advances Guido Kobbe, Tobias A.W. Holderried et al. 2
2 Final analysis of the GMALL-PH-01 trial: phase II study of standard chemotherapy in combination with dasatinib in first line treatment of Philadelphia chromosome positive acute lymphoblastic leukemia Leukemia & lymphoma Fabian Lang, Andreas Voß et al. 0
3 Dynamic Prediction of Mortality Risk Following Allogeneic Hematopoietic Stem Cell Transplantation SHILAP Revista de lepidopterología Sebastian Scharf, Paul Jäger et al. 0
4 Outcomes in patients with acute myeloid leukemia older than 70 years within the last 30 years, a single center experience Annals of Hematology Andrea Kündgen, Kathrin Nachtkamp et al. 0
5 Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies Cancers Paul Jäger, Johanna Tischer et al. 6
6 The predictive power of baseline metabolic and volumetric [18F]FDG PET parameters with different thresholds for early therapy failure and mortality risk in DLBCL patients undergoing CAR-T-cell therapy European Journal of Radiology Open Emil Novruzov, Guido Kobbe et al. 0
7 Comparison of Cytomegalovirus-Specific Immune Cell Response to Proteins versus Peptides Using an IFN-γ ELISpot Assay after Hematopoietic Stem Cell Transplantation Diagnostics Eva Wagner-Drouet, Daniel Teschner et al. 1
8 Prognostic impact of pretransplant measurable residual disease assessed by peripheral blood WT1‐mRNA expression in patients with AML and MDS European Journal Of Haematology Christina Rautenberg, Michael Lauseker et al. 15
9 Efficacy and Tolerability of High- versus Low-dose Lenalidomide Maintenance Therapy of Multiple Myeloma after Autologous Blood Stem Cell Transplantation Clinical Cancer Research Roland Fenk, Aristoteles Giagounidis et al. 4
10 Novel therapies in low- and high-risk myelodysplastic syndrome Expert Review of Hematology Ulrich Germing, Thomas Schroeder et al. 14
11 Comparison between Upfront Transplantation and different Pretransplant Cytoreductive Treatment Approaches in Patients with High-Risk Myelodysplastic Syndrome and Secondary Acute Myelogenous Leukemia Biology of Blood and Marrow Transplantation Thomas Schroeder, Michael Lauseker et al. 43
12 Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia Haematologica Stefanie Geyh, Manuel Rodríguez‐Paredes et al. 47
13 Favourable Outcome of Elderly Patients with Multiple Myeloma Treated with Tandem Melphalan 100 High-Dose Therapy, Autologous Stem Cell Transplantation and Novel Agents - a Single Center Experience Blood Judith Neukirchen, Ariane Dienst et al. 3
14 Change of prognosis of patients with myelodysplastic syndromes during the last 30 years Leukemia Research Judith Neukirchen, Kathrin Nachtkamp et al. 11
15 Risk models predicting survival after reduced‐intensity transplantation for myelofibrosis British Journal of Haematology Haefaa Alchalby, Tatjana Zabelina et al. 57
16 Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma Experimental Hematology Roland Fenk, Ulrich Steidl et al. 20
17 Exisulind induces apoptosis in advanced myelodysplastic syndrome (MDS) and acute myeloid leukaemia/MDS British Journal of Haematology Akos Czibere, Wolf Christian Prall et al. 11
18 Intensive Chemotherapy Is Not Recommended for Patients with AML or High-Risk MDS Aged over 60 Years with Complex Karyotype Anomalies. Blood Sabine Knipp, Barbara Hildebrandt et al. 6
19 Successful transplantation of peripheral blood stem cells mobilized by chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma Bone Marrow Transplantation Ulrich Steidl, Roland Fenk et al. 68
20 Idarubicin, melphalan and cyclophosphamide: an intensified high-dose regimen for the treatment of myeloma patients. PubMed A. Heyll, D. Söhngen et al. 7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Uday Popat Breakdown of academic impact, for papers by Ghulam Mufti Breakdown of academic impact, for papers by Nicolas Boissel Breakdown of academic impact, for papers by Yang O. Huh Breakdown of academic impact, for papers by Sherry Pierce Breakdown of academic impact, for papers by Jean‐Michel Cayuela Breakdown of academic impact, for papers by Diane C. Arthur Breakdown of academic impact, for papers by Petra Muus Breakdown of academic impact, for papers by Sally Arai Breakdown of academic impact, for papers by Attilio Olivieri
Rankless by CCL
2026